The Antibody Hit Generation and Screening Market Size is predicted to grow at an 9.78% CAGR during the forecast period for 2024-2031.
Antibody hit generation and screening is a vital step in developing therapeutic antibodies, focusing on identifying and selecting candidates that bind to a target antigen with high affinity and specificity. This process leverages various technologies like hybridoma technology, phage display, yeast display, ribosome display, and computational tools to create and screen extensive libraries of antibody variants. The goal is to identify the most promising candidates for further development, which are crucial in advancing antibody-based medicines for treating various diseases.
The application of antibody hit generation and screening is particularly significant in treating cancer, autoimmune diseases, and infectious diseases. By identifying antibodies that target specific antigens associated with these conditions, researchers can develop therapies that are more effective and have fewer side effects. The increasing prevalence of chronic diseases globally is a major driving factor in this market. As the incidence of conditions like cancer, autoimmune disorders, and infectious diseases rises, the demand for effective and targeted therapies grows. Antibody-based medicines developed through hit generation and screening have the potential to meet this need and improve patient outcomes.
The antibody hit generation and screening market is segmented by application, technologies, antibody type. By application the market is segmented into cancer, autoimmune diseases, infectious diseases, by technologies market is categorized into hit generation, phage display, yeast display, ribosome display, b-cell hybridoma technology, computational tools, screening. By antibody type market is categorized into humanized antibody, human antibody, chimeric antibody, murine antibody.
Phage display is a key technology in antibody hit generation and screening, known for its efficiency in identifying high-affinity antibodies from vast libraries. It enables the creation of billions of unique antibody variants, each linked to a bacteriophage, allowing for straightforward screening in a single experiment. The technology supports high-throughput screening (HTS) through a process called "biopanning," where antibodies are rapidly selected based on their binding strength to target antigens. Its customization and versatility, including the ability to construct libraries from different species and integrate with other technologies, make phage display an essential tool in modern drug discovery.
Humanized antibodies are driving growth in the antibody hit generation and screening market due to their enhanced safety and efficacy, reduced risk of immune reactions, and suitability for targeted therapies, particularly in treating cancer and autoimmune disorders. The rising demand for such therapies, combined with advancements in antibody engineering technologies like phage display and computational design, has accelerated the development of high-affinity humanized antibodies. Additionally, the rapid expansion of the biopharmaceutical industry, with increasing investments in R&D, is fueling the demand for humanized antibody discovery and screening.
North America is a hub for pharmaceutical and biotech firms, driving innovation in antibody discovery. Significant investments in R&D fuel advancements in antibody engineering and screening technologies, supported by cutting-edge methodologies like phage display and hybridoma technologies. Favorable regulatory frameworks further encourage the development and commercialization of new antibody-based therapies. Additionally, the rising demand for personalized medicine in the region increases the need for diverse antibody libraries tailored to specific patient needs.
| Report Attribute | Specifications |
| Growth Rate CAGR | CAGR of 9.78 % from 2024 to 2031 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
| Historic Year | 2019 to 2023 |
| Forecast Year | 2024-2031 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Application, Technologies, Antibody Type and By Region |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
| Competitive Landscape | F. Hoffmann-La Roche Ltd., AbbVie, Pfizer, AstraZeneca, Novartis, Eli Lilly, WuXi AppTec, Charles River Laboratories, Syngenta, BioLegend, Creative Biolabs, Eurofins CDMO, AbCellera, MorphoSys, Evelo Biosciences, Icos Therapeutics, Argenx, Kymab, Alnylam Pharmaceuticals, SAb Biotherapeutic |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Antibody Hit Generation and Screening Market by Application -
Antibody Hit Generation and Screening Market by Technologies -
Antibody Hit Generation and Screening Market by Antibody Type -
Antibody Hit Generation and Screening Market by Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Antibody Hit Generation and Screening Market Snapshot
Chapter 4. Global Antibody Hit Generation and Screening Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Application Estimates & Trend Analysis
5.1. by Application & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Application:
5.2.1. Cancer
5.2.2. Autoimmune diseases
5.2.3. Infectious diseases
Chapter 6. Market Segmentation 2: by Technologies Estimates & Trend Analysis
6.1. by Technologies & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Technologies:
6.2.1. Hit Generation
6.2.2. Phage display
6.2.3. Yeast display
6.2.4. Ribosome display
6.2.5. B-cell hybridoma technology
6.2.6. Computational tools
6.2.7. Screening
Chapter 7. Market Segmentation 3: by Antibody Type Estimates & Trend Analysis
7.1. by Antibody Type & Market Share, 2019 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Antibody Type:
7.2.1. Humanized Antibody
7.2.2. Human Antibody
7.2.3. Chimeric Antibody
7.2.4. Murine Antibody
Chapter 8. Antibody Hit Generation and Screening Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
8.1.2. North America Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Technologies, 2024-2031
8.1.3. North America Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Antibody Type, 2024-2031
8.1.4. North America Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.2. Europe
8.2.1. Europe Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
8.2.2. Europe Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Technologies, 2024-2031
8.2.3. Europe Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Antibody Type, 2024-2031
8.2.4. Europe Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.3. Asia Pacific
8.3.1. Asia Pacific Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
8.3.2. Asia Pacific Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Technologies, 2024-2031
8.3.3. Asia-Pacific Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Antibody Type, 2024-2031
8.3.4. Asia Pacific Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.4. Latin America
8.4.1. Latin America Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
8.4.2. Latin America Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Technologies, 2024-2031
8.4.3. Latin America Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Antibody Type, 2024-2031
8.4.4. Latin America Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
8.5.2. Middle East & Africa Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Technologies, 2024-2031
8.5.3. Middle East & Africa Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Antibody Type, 2024-2031
8.5.4. Middle East & Africa Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. F. Hoffmann-La Roche Ltd.
9.2.2. AbbVie
9.2.3. Pfizer
9.2.4. AstraZeneca
9.2.5. Novartis
9.2.6. Eli Lilly
9.2.7. WuXi AppTec
9.2.8. Charles River Laboratories
9.2.9. Syngenta
9.2.10. BioLegend
9.2.11. Creative Biolabs
9.2.12. Eurofins CDMO
9.2.13. AbCellera
9.2.14. MorphoSys
9.2.15. Evelo Biosciences
9.2.16. Icos Therapeutics
9.2.17. Argenx
9.2.18. Kymab
9.2.19. Alnylam Pharmaceuticals
9.2.20. SAb Biotherapeutics
9.2.21. Other Prominent Players